DEC 0 5 2002

## THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicant Sta Colin H. Dunstan

Serial No.:

09/389,545

Group Art Unit No.:

1646

Filed:

September 3, 1999

Examiner: Helms, Larry Ronald

For:

Compositions and Methods for the Prevention or Treatment

of Cancer and Bone Loss Associated with Cancer

Docket No.:

A-605

# REQUEST FOR CONTINUING EXAMINATION (RCE) **PURSUANT TO 37 CFR 1.114**

**Assistant Commissioner for Patents** Washington, D.C. 20231

Sir:

This is in response to the Advisory action dated July 1, 2002 in which Claims 23-40 were rejected. Applicant submits herewith a request for continuing examination and withdrawal of the rejections.

#### **AMENDMENT**

Please amend the application as follows:

### In the specification:

At page 45, replace the third paragraph with the following:

Plasmids encoding OPG[1-194]-Fc, OPG[1-201]-Fc, OPG[1-194]-FcΔC, OPG[1-201]-FcΔC, OPG[1-194]-FcG, and metFc∆C-OPG[22-194] for use in producing the corresponding OPG fusion polypeptides are constructed generally as described in WO97/23614 and in copending U.S. Serial No. 09/389,545, filed September 3, 1999, both of which are incorporated by reference. The polypeptide sequences are shown in Figures 3-8, respectively.

### In the claims:

Please cancel Claims 23-40 and add the following new claims:

#### **EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling number: EL360692602US

Date of Deposit:

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Bost Office to Addressee" sen indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C.

Lynne Buchsbaum